Snake Venom Components as Therapeutic Leads: A Critical Narrative Review of Established Medicines and Translational Barriers
Uzuazokaro Mark-Maria Agatemor
International Journal of Biochemistry Research & Review · pp. 100–107 · Published 3 Nov 2026
10.9734/ijbcrr/2026/v35i61183Abstract
Background: Snake venoms contain biologically active molecules that interact with enzymes, adhesion receptors and ion channels. These interactions have informed drug development, although toxicity and poor translation constrain many proposed applications. Objective: To critically examine the therapeutic relevance of snake venom components, distinguish demonstrated clinical utility from experimental activity, and identify requirements for further development. Approach: Targeted web searches of PubMed-indexed records and original publisher pages were conducted on 13 September 2026. Foundational discovery studies, randomised trials and selected mechanistic investigations were prioritised. Public prescribing information was consulted for established medicines. Evidence was organised by mechanism and experimental setting without meta-analysis or formal certainty grading. Findings: Bradykinin-potentiating peptides and disintegrins informed the development of captopril, eptifibatide and tirofiban. Their translation depended on molecular redesign and clinical evaluation rather than administration of crude venom. Defibrinogenating and fibrinolytic candidates illustrate less successful pathways: ancrod produced inconsistent stroke outcomes, and alfimeprase did not improve the principal clinical endpoint in placebo-controlled peripheral arterial occlusion studies. Textilinin-1, anticancer disintegrins, antimicrobial enzymes and mambalgins provide mechanistic leads. However, normal-cell toxicity, problematic cancer models and differences between rodent and human ion-channel pharmacology limit extrapolation. Conclusion: Snake venom is a productive source of pharmacological templates. Future progress requires defined molecular products, human-relevant target validation, exposure-linked safety assessment and clinically meaningful comparators. Claims of therapeutic benefit should reflect the level of evidence for each individual molecule.
Cited by 0
No indexed citations yet.
Related research
- Analyzing Different Acetyl Co-A Metabolizing Enzymes as Potential Drug Targets against Mycobacterium tuberculosis — shares topic coverage
- Indole-Based Macrocyclization by Metal-Catalyzed Approaches — shares topic coverage
- Hyphenated Techniques in Liquid Chromatography as Current Trends in Natural Products Analysis — shares topic coverage
- Sensitivity of NMR-based Metabolomics in Drug Discovery from Medicinal Plants — shares topic coverage
- Pharmacovigilance in Cameroon: Past, Present and Future Developments in Unlocking the Drug Development Process — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
0
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.